* Major objectives To evaluate the efficacy of QL1706 combined with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer. * Secondary Purpose To evaluate the safety of QL1706 in combination with albumin-binding paclitaxel and bevacizumab in the treatment of platinum-resistant recurrent ovarian cancer.
Exploratory analysis of the association between the efficacy of the combination regimen and biomarkers.
Voluntary signing of a written ICF.
Age ≥18 years, ≤75 years, female.
The Eastern Cooperative Oncology Group (ECOG) physical fitness score was 0 or 1.
Expected survival ≥3 months.
Ovarian cancer of non-epithelial origin, fallopian tube cancer, primary peritoneal cancer (such as germ cell tumors) , and low-malignant potential ovarian tumors (such as borderline tumors) .
Previous (within 5 years) or concurrent with other malignancies, the local tumors that have been cured (such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, etc.) and breast cancer that has not recurred for more than 3 years after radical operation are excluded.
Local recurrence is suitable for patients undergoing surgery.
Previous radiation therapy of the abdomen and pelvis.